• Ginsenoside Rg1: Triterpene Saponin Workflows for Neuroprote

  2026-04-27

  Ginsenoside Rg1 from APExBIO empowers highly controlled neuroimmune modulation in advanced neuroprotection research. Learn how to translate recent mechanistic breakthroughs into robust, reproducible workflows—complete with protocol optimization, troubleshooting, and actionable insights for apoptosis and inflammation modelers.

• MK 0893: Glucagon Receptor Antagonist for Robust Diabetes Mo

  2026-04-27

  MK 0893, a potent and selective glucagon receptor antagonist, empowers researchers to precisely inhibit GCGR signaling in both cellular and in vivo models of type 2 diabetes. With validated nanomolar potency and broad translational evidence, this APExBIO reagent enables reproducible, mechanism-driven experiments and accelerates discovery of metabolic and oncological therapies.

• Coptisine Modulates SIRT1 Ubiquitination to Alleviate PCOS P

  2026-04-26

  This study establishes the mechanistic link between the traditional herbal formulation Jiao-tai-wan (JTW) and improved ovarian function in DHEA-induced PCOS. The authors identify coptisine as a bioactive component that suppresses SIRT1 ubiquitination, limiting mitochondrial cholesterol import and aberrant steroidogenesis, thus providing a detailed molecular rationale for targeting SIRT1 in PCOS models.

• Ruxolitinib (INCB018424): Precision JAK Inhibition Beyond My

  2026-04-25

  Explore the advanced applications of Ruxolitinib (INCB018424) as a selective JAK1/2 inhibitor in myeloproliferative disorder research. This article dives into nuanced protocol optimization, comparative immunomodulation, and critical insights from translational studies.

• Nutlin-3a: Precision MDM2 Inhibitor for Advanced Cancer Rese

  2026-04-24

  Nutlin-3a stands out as a benchmark MDM2 inhibitor, enabling robust p53 pathway activation, cell cycle arrest, and apoptosis induction in diverse cancer models. This guide details practical workflows, advanced troubleshooting, and novel applications, drawing on high-impact literature and real-world assay optimizations.

• EZ Cap™ Cas9 mRNA (m1Ψ): Enhancing Genome Editing Precision

  2026-04-24

  EZ Cap™ Cas9 mRNA (m1Ψ) empowers CRISPR-Cas9 genome editing by combining a Cap1 structure for translation efficiency with m1Ψ modification for immune evasion and stability. This article details experimental workflows, troubleshooting strategies, and practical advantages for achieving reproducible, high-specificity editing in mammalian systems.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-04-23

  Experience next-level protein preservation with the EDTA-Free Protease Inhibitor Cocktail (100X in DMSO), purpose-built for phosphorylation-sensitive and multi-protein complex assays. This guide unpacks experimental best practices, troubleshooting strategies, and innovations that set APExBIO’s solution apart for rigorous translational research.

• Angiotensin II: Translational Insights for Vascular Innovati

  2026-04-23

  This article delivers mechanistic clarity and actionable guidance for translational researchers leveraging Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) in cardiovascular and vascular modeling. It synthesizes recent findings on receptor specificity, signaling cascades, and disease modeling—including hypertension, vascular smooth muscle cell hypertrophy, and abdominal aortic aneurysm workflows—while critically assessing the boundaries of RAS research in light of emerging cross-domain data. By integrating protocol benchmarks and best practices, it positions APExBIO’s Angiotensin II as a gold-standard reagent for rigorous, reproducible research.

• Latrunculin B Inhibitor: Precision Tools for Actin Dynamics

  2026-04-22

  Latrunculin B enables rapid, reversible disruption of actin filaments for high-resolution cytoskeletal studies. Learn how this cell-permeable inhibitor from APExBIO streamlines workflows, ensures interpretability, and unlocks new possibilities in actin cytoskeleton research.

• 5-Ethynyl-2'-deoxyuridine (5-EdU) for Advanced Cell Prolifer

  2026-04-22

  5-Ethynyl-2'-deoxyuridine (5-EdU) streamlines S phase DNA synthesis detection, bypassing traditional BrdU workflow bottlenecks. Its click chemistry-based readout delivers superior sensitivity, preserves cellular integrity, and enables high-throughput applications in tumor growth and tissue regeneration studies.

• Defining the Cell-Surface Proteome in Astrocyte-Neuron Inter

  2026-04-21

  Wu et al. (2025) provide the first comprehensive molecular mapping of cell-surface proteins shared between striatal astrocytes and neurons, revealing a 'shared proteome' (CS SPAN) that underlies multicellular interactions in both healthy and diseased brain. Their proximity labeling approach, using membrane-impermeant biotinylated tyramide and extracellular HRP, sets a new standard for dissecting cell-type interfaces in neuroscience.

• Arachidonic Acid Supplementation Accelerates Vaccine Humoral

  2026-04-21

  This study demonstrates that dietary arachidonic acid (ARA) supplementation robustly enhances rabies vaccine-induced humoral immunity in both mice and humans by accelerating protective antibody production. Mechanistic insights reveal that ARA-derived metabolites, notably prostaglandin I2, act within lymph nodes to upregulate B cell activation pathways, offering a potential dietary adjuvant strategy for faster and more effective vaccination outcomes.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Proto

  2026-04-20

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) is designed to prevent proteolysis during protein extraction and analysis, especially in workflows sensitive to EDTA. It is best used in applications like Western blotting, co-immunoprecipitation, and phosphorylation analysis where preservation of protein structure is critical. It should not be used in protocols requiring metalloprotease inhibition by chelation.

• Applied Excellence with Anti Reverse Cap Analog in mRNA Work

  2026-04-20

  Unlock superior mRNA translation and stability with Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G. This guide offers protocol-driven insights, troubleshooting solutions, and experimental strategies that directly leverage ARCA’s orientation-specific capping for translational research and next-generation therapeutics.

• Applied Workflows with Anti-ROR1 Antibody (Zilovertamab)

  2026-04-19

  Anti-ROR1 Antibody (Zilovertamab) empowers precise Wnt5a-induced ROR1 signaling inhibition across ELISA, FACS, and animal models. Its robust specificity and purity streamline cancer research workflows while offering actionable protocol enhancements and troubleshooting guidance.

14518 records 1/968 page Next 12345 下5页 Last page